000 03583nam a2200445 i 4500
999 _c361071
_d361071
001 361071
003 ES-MaUEC
005 20230102121318.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 210723s2021 sz a s |||| 0|eng d
020 _a9783030734404
024 7 _a10.1007/978-3-030-73440-4
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC280.B6
_b2021 EB
245 0 0 _aResistance to Targeted Therapies in Multiple Myeloma
_cedited by Silvia CW Ling, Steven Trieu
250 _aFirst edition 2021
264 1 _aCham
_bSpringer International Publishing
_c2021
264 4 _c2021
300 _a1 recurso en línea (XVII, 154 páginas)
_bilustraciones
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aResistance to Targeted Anti-Cancer Therapeutics
_x2196-551X
_v22
490 0 _aBiomedical and Life Sciences (SpringerNature-11642)
490 0 _aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505 0 _a1. The role of targeted therapy in multiple myeloma -- 2. Lenalidomide -- 3. Pomalidomide -- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma -- 5. Daratumumab -- 6. Elotuzumab -- 7. Histone deacetylase inhibitors -- 8. Bone targeted therapies -- 9. New targeted therapies for multiple myeloma under clinical investigation.
520 3 _aMultiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
988 _aSpringer_BiomedLife_2021
650 7 _2embne
_9160182
_aMieloma múltiple
700 1 _aLing, Silvia CW.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aTrieu, Steven.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9783030734398
776 0 8 _iPrinted edition:
_z9783030734411
776 0 8 _iPrinted edition:
_z9783030734428
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-73440-4
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2022
_dz
_ek
_zSI